Literature DB >> 26692418

Role of senescence marker p16 INK4a measured in peripheral blood T-lymphocytes in predicting length of hospital stay after coronary artery bypass surgery in older adults.

Aliaksei Pustavoitau1, Viachaslau Barodka2, Norman E Sharpless3, Chad Torrice4, Daniel Nyhan5, Dan E Berkowitz6, Ashish S Shah7, Karen J Bandeen Roche8, Jeremy D Walston9.   

Abstract

Adults older than 65 years undergo more than 120,000 coronary artery bypass (CAB) procedures each year in the United States. Chronological age alone, though commonly used in prediction models of outcomes after CAB, does not alone reflect variability in aging process; thus, the risk of complications in older adults. We performed a prospective study to evaluate a relationship between senescence marker p16(INK4a) expression in peripheral blood T-lymphocytes (p16 levels in PBTLs) with aging and with perioperative outcomes in older CAB patients. We included 55 patients age 55 and older, who underwent CAB in Johns Hopkins Hospital between September 1st, 2010 and March 25th, 2013. Demographic, clinical and laboratory data following outline of the Society of Thoracic Surgeons data collection form was collected, and p16 mRNA levels in PBTLs were measured using TaqMan® qRT-PCR. Associations between p16 mRNA levels in PBTLs with length of hospital stay, frailty status, p16 protein levels in the aortic and left internal mammary artery tissue, cerebral oxygen saturation, and augmentation index as a measure of vascular stiffness were measured using regression analyses. Length of hospital stay was the primary outcome of interest, and major organ morbidity, mortality, and discharge to a skilled nursing facility were secondary outcomes. In secondary analysis, we evaluated associations between p16 mRNA levels in PBTLs and interleukin-6 levels using regression analyses. Median age of enrolled patients was 63.5 years (range 56-81 years), they were predominantly male (74.55%), of Caucasian descent (85.45%). Median log2(p16 levels in PBTLs) were 4.71 (range 1.10-6.82). P16 levels in PBTLs were significantly associated with chronological age (mean difference 0.06 for each year increase in age, 95% CI 0.01-0.11) and interleukin 6 levels (mean difference 0.09 for each pg/ml increase in IL-6 levels, 95% CI 0.01-0.18). There were no significant associations with frailty status, augmentation index, cerebral oxygenation and p16 protein levels in blood vessels. Increasing p16 levels in PBTLs did not predict length of stay in the hospital (HR 1.10, 95% CI 0.87-1.40) or intensive care unit (HR 1.02, 95% CI 0.79-1.32). Additional evaluation of p16 levels in PBTLs as predictor of perioperative outcomes is required and should include additional markers of immune system aging as well as different outcomes after CAB in addition to length of hospital stay.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging biomarker; Chronological age; Coronary artery bypass; Frailty; Length of hospital stay; Peripheral blood T-lymphocytes; Senescence; p16(INK4a) levels

Mesh:

Substances:

Year:  2015        PMID: 26692418      PMCID: PMC4718794          DOI: 10.1016/j.exger.2015.12.003

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  40 in total

1.  DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

Authors:  Robert H te Poele; Andrei L Okorokov; Lesley Jardine; Jeffrey Cummings; Simon P Joel
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 2.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

3.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

4.  Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging.

Authors:  F Zindy; D E Quelle; M F Roussel; C J Sherr
Journal:  Oncogene       Date:  1997-07-10       Impact factor: 9.867

Review 5.  Inflammatory markers in population studies of aging.

Authors:  Tushar Singh; Anne B Newman
Journal:  Ageing Res Rev       Date:  2010-12-08       Impact factor: 10.895

6.  Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening.

Authors:  Anette Melk; Wipawee Kittikowit; Irwindeep Sandhu; Kieran M Halloran; Paul Grimm; Bernhard M W Schmidt; Philip F Halloran
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

Review 7.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

8.  Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation.

Authors:  A J Brenner; M R Stampfer; C M Aldaz
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

Review 9.  Four faces of cellular senescence.

Authors:  Francis Rodier; Judith Campisi
Journal:  J Cell Biol       Date:  2011-02-14       Impact factor: 10.539

10.  Frailty, fitness and late-life mortality in relation to chronological and biological age.

Authors:  Arnold B Mitnitski; Janice E Graham; Alexander J Mogilner; Kenneth Rockwood
Journal:  BMC Geriatr       Date:  2002-02-27       Impact factor: 3.921

View more
  7 in total

1.  A Quiescent Bcl11b High Stem Cell Population Is Required for Maintenance of the Mammary Gland.

Authors:  Shang Cai; Tomer Kalisky; Debashis Sahoo; Piero Dalerba; Weiguo Feng; Yuan Lin; Dalong Qian; Angela Kong; Jeffrey Yu; Flora Wang; Elizabeth Y Chen; Ferenc A Scheeren; Angera H Kuo; Shaheen S Sikandar; Shigeo Hisamori; Linda J van Weele; Diane Heiser; Sopheak Sim; Jessica Lam; Stephen Quake; Michael F Clarke
Journal:  Cell Stem Cell       Date:  2016-12-29       Impact factor: 24.633

Review 2.  Palliative Care of Cancer in the Older Patient.

Authors:  Lodovico Balducci; Dawn Dolan
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 3.  Immune Senescence, Immunosenescence and Aging.

Authors:  Kyoo-A Lee; Rafael R Flores; In Hwa Jang; Ashley Saathoff; Paul D Robbins
Journal:  Front Aging       Date:  2022-05-30

Review 4.  Cellular Senescence in the Treatment of Ovarian Cancer.

Authors:  Zehua Wang; Haiou Liu; Congjian Xu
Journal:  Int J Gynecol Cancer       Date:  2018-06       Impact factor: 3.437

5.  T lymphocyte senescence is attenuated in Parkinson's disease.

Authors:  Antonina Kouli; Melanie Jensen; Vanesa Papastavrou; Kirsten M Scott; Claire Kolenda; Craig Parker; Imtiaz H Solim; Marta Camacho; Carmen Martin-Ruiz; Caroline H Williams-Gray
Journal:  J Neuroinflammation       Date:  2021-10-13       Impact factor: 8.322

Review 6.  Cellular Senescence in Immunity against Infections.

Authors:  Veronica Marrella; Amanda Facoetti; Barbara Cassani
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

7.  Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study.

Authors:  Carmen Martin-Ruiz; Caroline H Williams-Gray; Alison J Yarnall; John J Boucher; Rachael A Lawson; Ruwani S Wijeyekoon; Roger A Barker; Claire Kolenda; Craig Parker; David J Burn; Thomas Von Zglinicki; Gabriele Saretzki
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.